BMS

Eye on ESMO: Day 1 – Access in spotlight before data deluge

https://pharmaphorum.com/esmo-2016/eye-esmo-day-one-access-issue-data-deluge/

BMS and Nektar to pair Opdivo with natural killer cell drug

https://pharmaphorum.com/news/bms-nektar-pair-opdivo-natural-killer-cell-drug/

Merck makes its move: Keytruda filed for first line lung cancer

https://pharmaphorum.com/news/merck-makes-move-keytruda-filed-first-line-lung-cancer/

Bavarian and BMS press on with Opdivo and cancer vaccine combo

https://pharmaphorum.com/news/bavarian-bms-press-opdivo-cancer-vaccine-combo/

BMS’ Opdivo stumbles in lung cancer, but could still maintain lead

https://pharmaphorum.com/news/opdivo-stumbles-lung-cancer-still-maintain-lead/

BMS files Opdivo for new use in US and Europe

https://pharmaphorum.com/news/bms-files-opdivo-new-use-us-eu/

NICE rejects Opdivo in advanced kidney cancer

https://pharmaphorum.com/news/nice-rejects-bms-opdivo-advanced-kidney-cancer/

1 2 3 4

Close in 10 seconds

Pharmaphorum.com

Search